9 Jan. 2021. The U.S. and India are set to produce two-thirds of the world’s Covid-19 vaccine doses by the end of this year, presenting worldwide distribution challenges. These data are drawn from a report on the German radio network Deutsche Welle and published yesterday by business data company Statista.
The Deutsche Welle story is based on statistics compiled by the life sciences data company Airfinity that calculated Covid-19 vaccine production capacities of various countries. The findings show the U.S. can produce 4.7 billion doses of Covid-19 vaccines beginning in 2020 and continuing through 2021, accounting for 41 percent of the 11.5 billion doses expected to be produced.
India, a leading pharma manufacturing country in normal times, anticipates producing another 3.1 billion doses, or 27 percent of the total. China, the U.K., Germany, and South Korea are expected to produce the remaining 3.7 billion vaccine doses.
As we’ve discussed a number of times in Science & Enterprise, manufacturing is one thing and distribution is quite another. Much of the world’s population will depend on the Covax facility, an international effort backed by World Health Organization, European Union, and non-government organizations to provide worldwide equitable access to Covid-19 vaccines. Up to now, the U.S. has declined to take part in Covax, but recent legislation and the incoming Biden administration will likely change that.
More from Science & Enterprise:
- Infographic – Vaccine Support Grows Across Ethnic Lines
- Infographic – Rich Nations Buy Most Covid-19 Vaccines
- Infographic – Willingness to Take Covid-19 Vaccine
* * *
You must be logged in to post a comment.